0001193125-22-104373.txt : 20220513 0001193125-22-104373.hdr.sgml : 20220513 20220413164306 ACCESSION NUMBER: 0001193125-22-104373 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 4D Molecular Therapeutics Inc. CENTRAL INDEX KEY: 0001650648 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473506994 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105052680 MAIL ADDRESS: STREET 1: 5858 HORTON STREET #455 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: 4D Molecular Therapeutics Inc DATE OF NAME CHANGE: 20150811 CORRESP 1 filename1.htm CORRESP

4D Molecular Therapeutics, Inc.

5858 Horton Street, #455

Emeryville, California 94608

April 13, 2022

VIA EDGAR AND E-MAIL

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:

Alan Campbell

 

  Re:

4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-263925)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-263925) (the “Registration Statement”) of 4D Molecular Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on April 15, 2022, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or Phillip Stoup at (415) 395-8216.

Thank you for your assistance in this matter.

 

Very truly yours,

 

4D MOLECULAR THERAPEUTICS, INC.

By:   /s/ August Moretti
  August Moretti
  Chief Financial Officer

 

cc:

David Kirn, M.D., 4D Molecular Therapeutics, Inc.

Scott Bizily, J.D., Ph.D., 4D Molecular Therapeutics, Inc.

Mark V. Roeder, Latham & Watkins LLP

Phillip S. Stoup, Latham & Watkins LLP